Litcius/Paper detail

Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial

Antoine Thiery-Vuillemin, Johann de Bono, Maha Hussain, Guilhem Roubaud, Giuseppe Procopio, Neal Shore, Karim Fizazi, Gabriel dos Anjos, Gwenaelle Gravis, Jae Young Joung, Nobuaki Matsubara, Daniel Castellano, Arnold Degboe, Chris Gresty, Jinyu Kang, Allison Allen, Christian Poehlein, Fred Saad

2022The Lancet Oncology38 citationsDOI

Topics & Concepts

MedicineProstate cancerHomologous recombinationOlaparibOncologyDrugInternal medicineQuality of life (healthcare)Hormonal therapyGeneCancerHormoneProstateDNA repairCancer researchMetastasisPARP inhibitorPoly ADP ribose polymeraseChemotherapyProstate Cancer Treatment and ResearchPARP inhibition in cancer therapyProstate Cancer Diagnosis and Treatment
Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial | Litcius